3 Undervalued Pharmaceuticals Stocks for Wednesday, November 13
Discover the top 3 undervalued Pharmaceuticals stocks for Wednesday, November 13 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Commentary & Analysis
4 Undervalued Biotechnology & Medical Research Stocks for Thursday, September 12
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Thursday, September 12 based on AAII’s Stock Grades.Jenna Brashear
4 Undervalued Biotechnology & Medical Research Stocks for Tuesday, August 13
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Tuesday, August 13 based on AAII’s Stock Grades.Eunice Kim
5 Undervalued Pharmaceuticals Stocks for Wednesday, January 17
Discover the top 5 undervalued Pharmaceuticals stocks for Wednesday, January 17 based on AAII’s Stock Grades.Eunice Kim
3 Undervalued Pharmaceuticals Stocks for Monday, November 20
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, November 20 based on AAII’s Stock Grades.Grace Malone
Financial Summary
| Share Statistics | KPRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.5 | $409.9 | 7% |
|
| Shares Out (Mil) | 6.2 | 44.5 | 16% |
|
| Institutional Ownership | 88.7% | 81.1% | 57% |
|
| Float (Mil) | 3.9 | 45.7 | 10% |
|
| Beta | -0.21 | 0.72 | 3% |
|
| Avg Daily Volume (000s) | 106 | 284 | 37% |
|
| Price Change (52-week) |
(36.7%) | 52.7% | 26% |
|
| Growth | KPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 5.7% | na |
|
| Net Income (5yr) | (9.4%) | (2.0%) | 30% |
|
| EPS (5yr) | 65.5% | 14.9% | 97 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 14.9% | (15.1%) | 72% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | KPRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $326 | na |
|
| Net Income (TTM) (Mil) | ($11) | ($11) | 28% |
|
| EPS (TTM) | ($2.294) | ($0.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($6) | 21% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $2 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 12% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $466 | 3% |
|
| Valuation | KPRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.57 | 1.96 | 13% |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | KPRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.7% | na |
|
| Net Margin | na | 3.4% | na |
|
| ROA | (39.4%) | (21.5%) | 14% |
|
| ROE | (56.4%) | (21.0%) | 14% |
|
| Liabilities to Assets | 29.1% | 31.8% | 20% |
|
| F-Score | 3 | 3 | 18% |
|
Kiora Pharmaceuticals, Inc. did not pass any screens on 11/5/2026.
